Antiretroviral Therapy

Optimizing Antiretroviral Therapy

The data guiding the dosing, efficacy and safety of medicines for children have lagged substantially as compared to the information available for adults. As a consequence, pediatricians faced with the prospect of confining their practice to medicines with adequate information have frequently resorted to prescribing medicines for unapproved uses (different dose, frequency, age group, route, indi...

Advances in antiretroviral therapy.

The 14th Conference on Retroviruses and Opportunistic Infections provided a forum for presentation of state-of-the-art research on antiretroviral therapy. This year's conference marked the first public presentation of phase III trials of the lead compounds in 2 new drug classes: maraviroc (a CCR5 inhibitor) and raltegravir (an HIV-1 integrase inhibitor). These agents are likely to be approved b...

[Angiolipomas and antiretroviral therapy].

In recent years, an association has been described between the use of protease inhibitors for antiretroviral therapy and the appearance of angiolipomas and lipomas, as well as with an increase in the number and size of those already present.1-3 A 40-year-old man consulted in 2005 for lesions that first appeared in 1998, and that had increased in number and size since then. Some were tender to p...

Stopping antiretroviral therapy.

Combination antiretroviral regimens continue to fail in some patients [1,2]. Here we consider a factor that may be important; i.e. how patients stop therapy. We previously postulated that if one drug in a regimen has a significantly longer half-life than others, and all agents are stopped simultaneously [3] then the patient will be taking essentially ‘functional monotherapy’ after the shorter h...

Benchmarks for antiretroviral therapy.